A review of the genetic and long-term effects of G-CSF injections in healthy donors: A reassuring lack of evidence for the development of haematological malignancies

Bone Marrow Transplantation

Volumn 50, Issue 3, 2015, Pages 334-340

  Shaw, B E ^a,b   Confer, D L ^c   Hwang, W ^d,e,f   Pulsipher, M A ^g,h  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c NATIONAL MARROW DONOR PROGRAM   (United States)

^d SINGAPORE GENERAL HOSPITAL   (Singapore)

^e DUKE NUS MEDICAL SCHOOL   (Singapore)

^f Singapore Cord Blood Bank ^*  (Singapore)

^g UNIVERSITY OF UTAH   (United States)

^h PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE MYELOBLASTIC LEUKEMIA; BLOOD CELL COUNT; CANCER INCIDENCE; CANCER RISK; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFECT; DRUG EXPOSURE; DRUG SAFETY; GENE EXPRESSION; HEMATOLOGIC MALIGNANCY; HUMAN; LYMPHOMA; MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; UNSPECIFIED SIDE EFFECT; CHEMICALLY INDUCED; DONOR; GENETICS; HEMATOLOGIC DISEASE; INJECTION;

GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC NEOPLASMS; HUMANS; INJECTIONS; TISSUE DONORS;

EID: 84938419338     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2014.278     Document Type: Review

References (42)

1. Passweg JR, Baldomero H, Peters C, Gaspar HB, Cesaro S, Dreger P et al. Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation. Bone Marrow Transplant 2014; 49: 744-750.
2. de Haas M, Kerst JM, van der Schoot CE, Calafat J, Hack CE, Nuijens JH et al. Granulocyte colony-stimulating factor administration to healthy volunteers: analysis of the immediate activating effects on circulating neutrophils. Blood 1994; 84: 3885-3894.
3. Anderlini P, Champlin RE. Biologic and molecular effects of granulocyte colonystimulating factor in healthy individuals: recent findings and current challenges. Blood 2008; 111: 1767-1772.
4. Bennett CL, Evens AM, Andritsos LA, Balasubramanian L, Mai M, Fisher MJ et al. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol 2006; 135: 642-650.
5. Nagler A, Korenstein-Ilan A, Amiel A, Avivi L. Granulocyte colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells. Exp Hematol 2004; 32: 122-130.
6. Pamphilon D, Mackinnon S, Nacheva E, Russell N, Wilson K, Clay M et al. The use of granulocyte colony-stimulating factor in volunteer blood and marrow registry donors. Bone Marrow Transplant 2006; 38: 699-700.
7. Rosenberg PS, Alter BP, Bolyard AA, Bonilla MA, Boxer LA, Cham B et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood 2006; 107: 4628-4635.
8. Gurion R, Gafter-Gvili A, Paul M, Vidal L, Ben-Bassat I, Yeshurun M et al. Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis. Haematologica 2009; 94: 712-719.
9. Donadieu J, Leblanc T, Bader Meunier B, Barkaoui M, Fenneteau O, Bertrand Y et al. Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group. Haematologica 2005; 90: 45-53.
10. Socie G, Mary JY, Schrezenmeier H, Marsh J, Bacigalupo A, Locasciulli A et al. Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood 2007; 109: 2794-2796.
11. Kojima S, Ohara A, Tsuchida M, Kudoh T, Hanada R, Okimoto Y et al. Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood 2002; 100: 786-790.
12. Confer DL, Miller JP. Long-term safety of filgrastim (rhG-CSF) administration. Br J Haematol 2007; 137: 77-78 author reply 79-80.
13. Goldman JM, Madrigal JA, Pamphilon D. Possible harmful effects of short course granulocyte colony-stimulating factor in normal donors. Br J Haematol 2006; 135: 651-652.
14. Pulsipher MA, Chitphakdithai P, Miller JP, Logan BR, King RJ, Rizzo JD et al. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood 2009; 113: 3604-3611.
15. Pulsipher MA, Chitphakdithai P, Logan BR, Shaw BE, Wingard JR, Lazarus HM et al. Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. Blood 2013; 121: 197-206.
16. Miller JP, Perry EH, Price TH, Bolan CD Jr, Karanes C, Boyd TM et al. Recovery and safety profiles of marrow and PBSC donors: experience of the National Marrow Donor Program. Biol Blood Marrow Transplant 2008; 14: 29-36.
17. Halter J, Kodera Y, Ispizua AU, Greinix HT, Schmitz N, Favre G et al. Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica 2009; 94: 94-101.
18. Holig K, Kramer M, Kroschinsky F, Bornhauser M, Mengling T, Schmidt AH et al. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. Blood 2009; 114: 3757-3763.
19. Avalos BR, Lazaryan A, Copelan EA. Can G-CSF cause leukemia in hematopoietic stem cell donors? Biol Blood Marrow Transplant 2011; 17: 1739-1746.
20. Storek J, Dawson MA, Maloney DG. Normal T, B, and NK cell counts in healthy donors at 1 year after blood stem cell harvesting. Blood 2000; 95: 2993-2994.
21. Marmier-Savet C, Larosa F, Legrand F, Witz B, Michallet M, Ranta D et al. Persistence of lymphocyte function perturbations after granulocyte-colonystimulating factor mobilization and cytapheresis in normal peripheral blood stem cell donors. Transfusion 2010; 50: 2676-2685.
22. Cavallaro AM, Lilleby K, Majolino I, Storb R, Appelbaum FR, Rowley SD et al. Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 2000; 25: 85-89.
23. Tassi C, Tazzari PL, Bonifazi F, Giudice V, Nannetti A, Ricci F et al. Short- and long-term haematological surveillance of healthy donors of allogeneic peripheral haematopoietic progenitors mobilized with G-CSF: a single institution prospective study. Bone Marrow Transplant 2005; 36: 289-294.
24. Quillen K, Byrne P, Yau YY, Leitman SF. Ten-year follow-up of unrelated volunteer granulocyte donors who have received multiple cycles of granulocyte-colonystimulating factor and dexamethasone. Transfusion 2009; 49: 513-518.
25. Kaplinsky C, Trakhtenbrot L, Hardan I, Reichart M, Daniely M, Toren A et al. Tetraploid myeloid cells in donors of peripheral blood stem cells treated with rhG-CSF. Bone Marrow Transplant 2003; 32: 31-34.
26. Shapira MY, Kaspler P, Samuel S, Shoshan S, Or R. Granulocyte colony stimulating factor does not induce long-term DNA instability in healthy peripheral blood stem cell donors. Am J Hematol 2003; 73: 33-36.
27. Hirsch B, Oseth L, Cain M, Trader E, Pulkrabek S, Lindgren B et al. Effects of granulocyte-colony stimulating factor on chromosome aneuploidy and replication asynchrony in healthy peripheral blood stem cell donors. Blood 2011; 118: 2602-2608.
28. Marmier-Savet C, Larosa F, Legrand F, Witz B, Michallet M, Ranta D et al. G-CSF-induced aneuploidy does not affect CD34+ cells and does not require cell division. Blood 2010; 115: 910-911.
29. Olnes MJ, Poon A, Miranda SJ, Pfannes L, Tucker Z, Loeliger K et al. Effects of granulocyte-colony-stimulating factor on Monosomy 7 aneuploidy in healthy hematopoietic stem cell and granulocyte donors. Transfusion 2012; 52: 537-541.
30. Graf L, Heimfeld S, Torok-Storb B. Comparison of gene expression in CD34+ cells from bone marrow and G-CSF-mobilized peripheral blood by high-density oligonucleotide array analysis. Biol Blood Marrow Transplant 2001; 7: 486-494.
31. Baez A, Martin-Antonio B, Piruat JI, Prats C, Alvarez-Laderas I, Barbado MV et al. Granulocyte colony-stimulating factor produces long-term changes in gene and microRNA expression profiles in CD34+ cells from healthy donors. Haematologica 2014; 99: 243-251.
32. Amariglio N, Jacob-Hirsch J, Shimoni A, Leiba M, Rechavi G, Nagler A. Changes in gene expression pattern following granulocyte colony-stimulating factor administration to normal stem cell sibling donors. Acta Haematol 2007; 117: 68-73.
33. Hernandez JM, Castilla C, Gutierrez NC, Isidro IM, Delgado M, de las Rivas J et al. Mobilisation with G-CSF in healthy donors promotes a high but temporal deregulation of genes. Leukemia 2005; 19: 1088-1091.
34. Hasenclever D, Sextro M. Safety of AlloPBPCT donors: biometrical considerations on monitoring long term risks. Bone Marrow Transplant 1996; 17: S28-S30.
35. Pulsipher MA, Chitphakdithai P, Logan BR, Navarro WH, Levine JE, Miller JP et al. Lower risk of serious adverse events and no increased risk of cancer after PBSC versus bone marrow donation. Blood 2014; 123: 3655-3663.
36. Holig K. G-CSF in Healthy Allogeneic Stem Cell Donors. Transfus Med Hemother 2013; 40: 225-235.
37. Schmidt AH, Mengling T, Pingel J, Rall G, Ehninger G. Follow-up of 12, 559 Unrelated Donors of Peripheral Blood Stem Cells or Bone Marrow. Blood (ASH Annual Meeting Abstracts) 2010; 116 Abstract 365.
38. Wiersum-Osselton JC, van Walraven SM, Bank I, Lenselink AM, Fibbe WE, van der Bom JG et al. Clinical outcomes after peripheral blood stem cell donation by related donors: a Dutch single-center cohort study. Transfusion 2013; 53: 96-103.
39. de la Rubia J, de Arriba F, Arbona C, Pascual MJ, Zamora C, Insunza A et al. Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry. Haematologica 2008; 93: 735-740.
40. Mueller MM, Bialleck H, Bomke B, Brauninger S, Varga C, Seidl C et al. Safety and efficacy of healthy volunteer stem cell mobilization with filgrastim G-CSF and mobilized stem cell apheresis: results of a prospective longitudinal 5-year follow-up study. Vox Sang 2013; 104: 46-54.
41. Kodera Y, Yamamoto K, Harada M, Morishima Y, Dohy H, Asano S et al. PBSC collection from family donors in Japan: a prospective survey. Bone Marrow Transplant 2014; 49: 195-200.
42. Jeger A, Favre G, Lutz JM, Stern M, Usel M, Rovo A et al. Tumor incidence in related hematopoietic stem cell donors. Bone Marrow Transplant 2011; 46: 1240-1244.